The generation of HIV bnAbs may be one of the greatest feats of the human immune system
and our best hope of finally creating an HIV vaccine. The striking amount of somatic …

Since their discovery, antibodies capable of broad neutralisation have been at the forefront
of HIV-1 research and are of particular interest due to in vivo passive transfer studies …

Germinal centres are the engines of antibody evolution. Here, using human
immunodeficiency virus (HIV) Env protein immunogen priming in rhesus monkeys followed …

The development of a protective vaccine remains a top priority for the control of the HIV/AIDS
pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing …

B cell receptor (BCR) sequencing is a powerful tool for interrogating immune responses to
infection and vaccination, but it provides limited information about the antigen specificity of …

Conventional immunization strategies will likely be insufficient for the development of a
broadly neutralizing antibody (bnAb) vaccine for HIV or other difficult pathogens because of …

The development of stabilized recombinant HIV envelope trimers that mimic the virion
surface molecule has increased enthusiasm for a neutralizing antibody (nAb)-based HIV …

INTRODUCTION A major goal of HIV-1 vaccine development is to identify immunogens
capable of inducing protective titers of broadly neutralizing antibodies (bNAbs) against …

3BNC117 is a broad and potent neutralizing antibody to HIV-1 that targets the CD4 binding
site on the viral envelope spike. When administered passively, this antibody can prevent …

Eliciting HIV-1-specific broadly neutralizing antibodies (bNAbs) remains a challenge for
vaccine development, and the potential of passively delivered bNAbs for prophylaxis and …